|
Apr 8
|
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
|
|
Apr 6
|
2 Biotech Stocks to Buy Hand Over Fist in April
|
|
Apr 2
|
Outperforming ETF manager names a potential ‘50-bagger’ in the stock market
|
|
Mar 29
|
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
|
|
Mar 29
|
Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week
|
|
Mar 25
|
A Comprehensive Look at Sarepta's Growth and Innovation
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 14
|
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
|
|
Mar 13
|
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
|
|
Mar 12
|
Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Mar 11
|
Billionaire Ray Dalio and Insiders Love These 10 Stocks
|
|
Mar 7
|
Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Mar 4
|
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
|
|
Mar 4
|
Sarepta Therapeutics to Present at Upcoming Investor Conferences
|
|
Feb 23
|
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
|
|
Feb 21
|
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
|
|
Feb 21
|
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
|
|
Feb 20
|
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
|
Jan 16
|
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
|